- Home
- VIGL vs UEIC Comparison
VIGL vs UEIC Comparison
Compare VIGL & UEIC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- VIGL
- UEIC
- Stock Information
- Founded
- VIGL 2020
- UEIC 1986
- Country
- VIGL United States
- UEIC United States
- Employees
- VIGL N/A
- UEIC N/A
- Industry
- VIGL Biotechnology: Pharmaceutical Preparations
- UEIC Consumer Electronics/Appliances
- Sector
- VIGL Health Care
- UEIC Consumer Staples
- Exchange
- VIGL Nasdaq
- UEIC Nasdaq
- Market Cap
- VIGL 95.2M
- UEIC 150.4M
- IPO Year
- VIGL 2022
- UEIC 1993
- Fundamental
- Price
- VIGL $1.70
- UEIC $10.83
- Analyst Decision
- VIGL Buy
- UEIC Strong Buy
- Analyst Count
- VIGL 6
- UEIC 2
- Target Price
- VIGL $16.60
- UEIC $14.50
- AVG Volume (30 Days)
- VIGL 387.1K
- UEIC 53.0K
- Earning Date
- VIGL 11-07-2024
- UEIC 02-13-2025
- Dividend Yield
- VIGL N/A
- UEIC N/A
- EPS Growth
- VIGL N/A
- UEIC N/A
- EPS
- VIGL N/A
- UEIC N/A
- Revenue
- VIGL N/A
- UEIC $382,019,000.00
- Revenue This Year
- VIGL N/A
- UEIC N/A
- Revenue Next Year
- VIGL N/A
- UEIC $5.38
- P/E Ratio
- VIGL N/A
- UEIC N/A
- Revenue Growth
- VIGL N/A
- UEIC N/A
- 52 Week Low
- VIGL $1.60
- UEIC $7.53
- 52 Week High
- VIGL $6.06
- UEIC $14.20
- Technical
- Relative Strength Index (RSI)
- VIGL 23.30
- UEIC 45.11
- Support Level
- VIGL $1.60
- UEIC $10.64
- Resistance Level
- VIGL $2.46
- UEIC $11.88
- Average True Range (ATR)
- VIGL 0.16
- UEIC 0.45
- MACD
- VIGL -0.02
- UEIC -0.21
- Stochastic Oscillator
- VIGL 11.63
- UEIC 10.22
About VIGL Vigil Neuroscience Inc.
Vigil Neuroscience Inc is a microglia-focused therapeutics company treating both rare and common neurodegenerative diseases by restoring the vigilance of microglia, the sentinel cells of the brain's immune system. It is utilizing the tools of modern neuroscience drug development across multiple therapeutic modalities to rapidly deliver precision-based therapies to improve the lives of patients and families. Its clinical candidate, iluzanebart, is currently being studied in IGNITE, a Phase 2 PoC trial and the first-ever interventional trial in ALSP patients. The company is also developing VG-3927, an orally available small molecule TREM2 agonist for the treatment of common neurodegenerative diseases associated with microglial dysfunction.
About UEIC Universal Electronics Inc.
Universal Electronics Inc is a United States-based company that principally designs, develops, manufactures, ships, and supports control and sensor technology solutions and a broad line of universal control systems, audio-video (AV) accessories, wireless security, and smart home products that are used by the world's brands in the video services, consumer electronics, security, home automation, climate control and home appliance markets. It generates its total revenue from the United States.